<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217565</url>
  </required_header>
  <id_info>
    <org_study_id>1986-014</org_study_id>
    <secondary_id>2017-000953-38</secondary_id>
    <secondary_id>MK-1986-014</secondary_id>
    <nct_id>NCT03217565</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)</brief_title>
  <official_title>A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to describe the single-dose, and multiple dose
      pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral
      suspension of tedizolid phosphate, when administered to pediatric participants, full-term
      neonates, and preterm neonates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">July 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-last of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to time of last quantifiable drug concentration (AUC0-last) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity (AUC0-inf) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Maximum concentration (Cmax) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Time to reach Cmax (Tmax) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Apparent terminal half-life (t1/2) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to time of last quantifiable drug concentration of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Maximum concentration of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Time to reach Cmax of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Apparent terminal half-life of plasma tedizolid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to Day 21</time_frame>
    <description>Number of participants with one or more adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants who discontinued from study due to an AE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Gram-Positive Infections</condition>
  <arm_group>
    <arm_group_label>IV Tedizolid Phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered intravenously (IV). For body weight &lt;10 kg: 3 mg/kg; for body weight 10 to &lt;30 kg: 2.5 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Suspension Tedizolid Phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of tedizolid phosphate administered as an oral suspension. For body weight &lt;10 kg: 3 mg/kg; for body weight 10 to &lt;30 kg: 2.5 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Tedizolid Phosphate</intervention_name>
    <description>A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.</description>
    <arm_group_label>IV Tedizolid Phosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Suspension Tedizolid Phosphate</intervention_name>
    <description>A single dose of tedizolid phosphate administered as an oral suspension.</description>
    <arm_group_label>Oral Suspension Tedizolid Phosphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is receiving prophylaxis for or has a confirmed or suspected infection with
             gram-positive bacteria and receiving concurrent antibiotic treatment with gram
             -positive antibacterial activity.

          -  Is at least 1 kg in weight.

          -  Is in stable condition as determined from medical history, physical examination,
             electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.

          -  Has no clinically significant ECG abnormalities.

          -  Has sufficient vascular access to receive trial drug, and allow for required blood
             draws.

          -  Is able to receive medication by mouth, for those dosed with oral suspension.

        Exclusion Criteria:

          -  Has a history of seizures, other than febrile seizures, clinically significant cardiac
             arrhythmia or condition, moderate or severe renal impairment, or any physical
             condition that could interfere with the interpretation of the study results, as
             determined by the Investigator.

          -  Has used rifampin within 14 days prior to dosing.

          -  Has used or will be using proton pump inhibitors, H2 blockers, or antacids (for
             participants in Part B, i.e, oral suspension dose) at any time from 24 hours prior to
             dosing through 24 hours after dosing..

          -  Has a recent (3-month) history or current infection with viral hepatitis or other
             significant hepatic disease.

          -  Has a history of drug allergy or hypersensitivity to oxazolidinones.

          -  Has had significant blood loss.

          -  Need for oral administration of topotecan, rosuvastatin, irinotecan, or methotrexate
             during administration of oral study drug.

          -  Used monoamine oxidase inhibitors (MAOIs) or serotonergic agents including tricyclic
             antidepressants, selective serotonin reuptake inhibitors (SSRIs), and serotonin
             5-hydroxytryptamine receptor agonists (triptans), meperidine, or buspirone within 14
             days prior to study, or planned use while on study.

          -  Has received another investigational product within the 30 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital ( Site 1012)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County ( Site 1001)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-509-4791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital ( Site 1021)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-939-7424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 1022)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-6285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center. ( Site 1004)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>225-765-5956</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis Children's Hospital ( Site 1020)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital ( Site 1000)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-587-6293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center - 1- Sevlievo EOOD ( Site 2207)</name>
      <address>
        <city>Sevlievo</city>
        <state>Gabrovo</state>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359877127333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Sv. Ivan Rilski EOOD ( Site 2201)</name>
      <address>
        <city>Kozloduy</city>
        <state>Vratsa</state>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Deva Maria ( Site 2208)</name>
      <address>
        <city>Burgas</city>
        <zip>8127</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359884386907</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT City Clinic Sv. Georgi EOOD ( Site 2202)</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359887397013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Ruse ( Site 2204)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359813986</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev AD ( Site 2209)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359888209200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Vicente Fundacion ( Site 1103)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 1106)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5753369999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 1102)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+57233190904022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus HF ( Site 1604)</name>
      <address>
        <city>Loerenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4741469314</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssykehus, Helse Stavanger ( Site 1601)</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+47515159940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital. ( Site 1600)</name>
      <address>
        <city>Trondheim</city>
        <state>Sor-Trondelag</state>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4772251241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssjukehus ( Site 1602)</name>
      <address>
        <city>Bergen</city>
        <state>Vestfold</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+475975720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust ( Site 1700)</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441223216555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary ( Site 1702)</name>
      <address>
        <city>Newcastle</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441912821527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust ( Site 1704)</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441512525570</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens NHS Foundation Trust Hospital ( Site 1703)</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441512284811</phone>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tedizolid</mesh_term>
    <mesh_term>Tedizolid phosphate</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

